119
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Association of Tim-4 expression in monocyte subtypes with clinical course and prognosis in acute ischemic stroke patients

, , , , &
Pages 906-916 | Received 06 Jun 2019, Accepted 19 Dec 2019, Published online: 10 Jan 2020

References

  • Zerna C, Hegedus J, Hill MD. Evolving treatments for acute ischemic stroke. Circ Res. 2016;118(9):1425–1442.
  • Alberto C, Lavinia D, Massimo DS. Intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:1178–1179.
  • Kaito M, Araya S, Gondo Y, et al. Relevance of distinct monocyte subsets to clinical course of ischemic stroke patients. PLoS One. 2013;8(8):e69409.
  • Urra X, Cervera A, Obach V, et al. Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke. 2009;40(4):1262–1268.
  • Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17(7):796–808.
  • Urra X, Villamor N, Amaro S, et al. Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab. 2009;29(5):994–1002.
  • Foulkes MA, Wolf PA, Price TR, et al. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke. 1988;19(5):547–554.
  • Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.
  • Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74–e80.
  • Weber C, Belge KU, von Hundelshausen P, et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol. 2000;67(5):699–704.
  • Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14 + CD16 + DR++ monocytes are a major source of TNF. J Immunol. 2002;168(7):3536–3542.
  • Baghdadi M, Yoneda A, Yamashina T, et al. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity. 2013;39(6):1070–1081.
  • Miyanishi M, Tada K, Koike M, et al. Identification of Tim4 as a phosphatidylserine receptor. Nature. 2007;450(7168):435–439.
  • Abe Y, Kamachi F, Kawamoto T, et al. TIM-4 has dual function in the induction and effector phases of murine arthritis. J Immunol. 2013;191(9):4562–4572.
  • Xu L, Ye Z, Wang B, et al. Tim-4 expression increases in ischemic stroke patients and is associated with poor outcome. J Neuroimmunol. 2018;316:1–6.
  • Chamorro A, Horcajada JP, Obach V, et al. The early systemic prophylaxis of infection after stroke study: a randomized clinical trial. Stroke. 2005;36(7):1495–1500.
  • Zhao D, Hou N, Cui M, et al. Increased T cell immunoglobulin and mucin domain 3 positively correlate with systemic IL-17 and TNF-alpha level in the acute phase of ischemic stroke. J Clin Immunol. 2011;31(4):719–727.
  • Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012;32(9):1677–1698.
  • Gu L, Jian Z, Stary C, et al. T cells and cerebral ischemic stroke. Neurochem Res. 2015;40(9):1786–1791.
  • Zhao P, Xu L, Wang P, et al. Increased expression of human T-cell immunoglobulin- and mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus. Cell Mol Immunol. 2010;7(2):152–156.
  • Li J, Zhao X, Liu X, et al. Disruption of TIM-4 in dendritic cell ameliorates hepatic warm IR injury through the induction of regulatory T cells. Mol Immunol. 2015;66(2):117–125.
  • Fang XY, Xu WD, Pan HF, et al. Novel insights into Tim-4 function in autoimmune diseases. Autoimmunity. 2015;48(4):189–195.
  • Chen D, He J, Lu C, et al. Increased expression of T cell immunoglobulin and mucin domain 4 is positively associated with the disease severity of patients with ankylosing spondylitis. Inflammation. 2015;38(3):935–940.
  • Kobayashi N, Karisola P, Ena-Cruz V, et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity. 2007;27(6):927–940.
  • Miyake Y, Asano K, Kaise H, et al. Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. J Clin Invest. 2007;117(8):2268–2278.
  • Rodriguez-Manzanet R, Sanjuan MA, Wu HY, et al. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci USA. 2010;107(19):8706–8711.
  • Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33(3):375–386.
  • Albacker LA, Yu S, Bedoret D, et al. TIM-4, expressed by medullary macrophages, regulates respiratory tolerance by mediating phagocytosis of antigen-specific T cells. Mucosal Immunol. 2013;6(3):580–590.
  • Yeung MY, McGrath MM, Nakayama M, et al. Interruption of dendritic cell-mediated TIM-4 signaling induces regulatory T cells and promotes skin allograft survival. J Immunol. 2013;191(8):4447–4455.
  • Schlitt A, Heine GH, Blankenberg S, et al. CD14 + CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost. 2004;92:419–424.
  • Wrigley BJ, Shantsila E, Tapp LD, et al. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J Clin Invest. 2013;43(2):121–130.
  • Skrzeczynska-Moncznik J, Bzowska M, Loseke S, et al. Peripheral blood CD14high CD16+ monocytes are main producers of IL-10. Scand J Immunol. 2008;67:152–159.
  • Szaflarska A, Baj-Krzyworzeka M, Siedlar M, et al. Antitumor response of CD14+/CD16+ monocyte subpopulation. Exp Hematol. 2004;32(8):748–755.
  • Xu LY, Qi JN, Liu X, et al. Tim-4 inhibits NO generation by murine macrophages. PLoS One. 2015;10(4):e0124771.
  • Rossol M, Heine H, Meusch U, et al. LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol. 2011;31(5):379–446.
  • Meng C, Zhang JC, Shi RL, et al. Inhibition of interleukin-6 abolishes the promoting effects of pair housing on post-stroke neurogenesis. Neuroscience. 2015;307:160–170.
  • Acalovschi D, Wiest T, Hartmann M, et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke. 2003;34(8):1864–1869.
  • Arboix A, Blanco-Rojas L, Martí-Vilalta JL. Advancements in understanding the mechanisms of symptomatic lacunar ischemic stroke: translation of knowledge to prevention strategies. Expert Rev Neurother. 2014;14(3):261–276.
  • Blanco-Rojas L, Arboix A, Canovas D, et al. Cognitive profile in patients with a first-ever lacunar infarct with and without silent lacunes: a comparative study. BMC Neurol. 2013;13(1):203.
  • Jacova C, Pearce LA, Costello R, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol. 2012;72(3):351–362.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.